Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

19.6K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

14.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

7.2K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
7.2K
The Proteasome02:18

The Proteasome

10.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.7K
The Proteasome01:13

The Proteasome

2.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutrophil cathepsin G potentiates biased signaling through protease-activated receptor 4.

Blood advances·2026
Same author

Neutrophil cathepsin G potentiates biased signaling through protease-activated receptor 4.

Blood advances·2025
Same author

Elucidating the dynamics of integrin αIIbβ3 from native platelet membranes by cryo-EM with build-and-retrieve method.

Blood advances·2025
Same author

Differentiating Aggressive from Nonaggressive Prostate Cancer Using Unconjugated Contrast Agents.

ACS applied materials & interfaces·2025
Same author

The <i>Plasmodium falciparum</i> NCR1 transporter is an antimalarial target that exports cholesterol from the parasite's plasma membrane.

Science advances·2024
Same author

Elucidating the dynamics of Integrin αIIbβ3 from native platelet membranes by cryo-EM with build and retrieve method.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Apr 16, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K

PARtitioning protease signaling.

Marvin T Nieman1

  • 1CASE WESTERN RESERVE UNIVERSITY.

Blood
|March 21, 2015
PubMed
Summary

Researchers developed novel parmodulins, a new class of protease-activated receptor-1 (PAR1) inhibitors. These compounds block inflammation while preserving protective cell signals, offering potential therapeutic benefits.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protease-activated receptor-1 (PAR1) is a key mediator of cellular signaling.
  • PAR1 activation triggers both proinflammatory and cytoprotective pathways in endothelial cells.
  • Selective modulation of PAR1 signaling remains a therapeutic challenge.

Purpose of the Study:

  • To identify and characterize novel inhibitors of PAR1.
  • To develop compounds that selectively block proinflammatory PAR1 signaling while sparing cytoprotective pathways.
  • To explore the therapeutic potential of targeting specific PAR1 signaling cascades.

Main Methods:

  • Development of a novel class of small molecules, termed parmodulins.
  • Biochemical assays to assess the interaction of parmodulins with PAR1.

More Related Videos

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

1.3K
Determining Membrane Protein Topology Using Fluorescence Protease Protection FPP
08:14

Determining Membrane Protein Topology Using Fluorescence Protease Protection FPP

Published on: April 20, 2015

18.5K

Related Experiment Videos

Last Updated: Apr 16, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

1.3K
Determining Membrane Protein Topology Using Fluorescence Protease Protection FPP
08:14

Determining Membrane Protein Topology Using Fluorescence Protease Protection FPP

Published on: April 20, 2015

18.5K
  • Cell-based assays to evaluate the effects of parmodulins on proinflammatory and cytoprotective signaling pathways in endothelial cells.
  • Investigation of the specific G protein pathways (Gαq vs. Gα12/13) modulated by parmodulins.

    • Main Results:

    • Aisiku et al. describe parmodulins, a novel class of PAR1 inhibitors.
    • Parmodulins selectively inhibit the Gαq signaling pathway downstream of PAR1.
    • These inhibitors effectively block proinflammatory signaling while preserving cytoprotective signaling in endothelial cells.
    • The compounds target the cytoplasmic face of PAR1, demonstrating pathway selectivity.

    Conclusions:

    • Parmodulins represent a novel therapeutic strategy for modulating PAR1 activity.
    • Selective inhibition of specific G protein pathways offers a way to dissociate desired from undesired cellular responses.
    • This approach may lead to improved therapeutic outcomes in conditions involving PAR1 dysregulation.